- Home
- IOVA vs CNNE Comparison
IOVA vs CNNE Comparison
Compare IOVA & CNNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- CNNE
- Stock Information
- Founded
- IOVA 2007
- CNNE 2014
- Country
- IOVA United States
- CNNE United States
- Employees
- IOVA N/A
- CNNE N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- CNNE Restaurants
- Sector
- IOVA Health Care
- CNNE Consumer Discretionary
- Exchange
- IOVA Nasdaq
- CNNE Nasdaq
- Market Cap
- IOVA 975.1M
- CNNE 1.1B
- IPO Year
- IOVA N/A
- CNNE N/A
- Fundamental
- Price
- IOVA $2.31
- CNNE $18.68
- Analyst Decision
- IOVA Buy
- CNNE Buy
- Analyst Count
- IOVA 11
- CNNE 3
- Target Price
- IOVA $11.90
- CNNE $23.33
- AVG Volume (30 Days)
- IOVA 10.3M
- CNNE 628.7K
- Earning Date
- IOVA 11-06-2025
- CNNE 11-11-2025
- Dividend Yield
- IOVA N/A
- CNNE 3.28%
- EPS Growth
- IOVA N/A
- CNNE N/A
- EPS
- IOVA N/A
- CNNE N/A
- Revenue
- IOVA $241,525,000.00
- CNNE $437,200,000.00
- Revenue This Year
- IOVA $68.14
- CNNE N/A
- Revenue Next Year
- IOVA $56.64
- CNNE N/A
- P/E Ratio
- IOVA N/A
- CNNE N/A
- Revenue Growth
- IOVA 636.99
- CNNE N/A
- 52 Week Low
- IOVA $1.64
- CNNE $15.92
- 52 Week High
- IOVA $12.51
- CNNE $22.36
- Technical
- Relative Strength Index (RSI)
- IOVA 53.84
- CNNE 50.98
- Support Level
- IOVA $2.13
- CNNE $18.08
- Resistance Level
- IOVA $2.31
- CNNE $19.00
- Average True Range (ATR)
- IOVA 0.13
- CNNE 0.43
- MACD
- IOVA 0.02
- CNNE 0.02
- Stochastic Oscillator
- IOVA 72.97
- CNNE 68.54
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
About CNNE Cannae Holdings Inc.
Cannae Holdings Inc is a holding company that manages and operates a group of companies and investments. The company's reportable segments are Restaurant Group, Dun & Bradstreet, Alight, BKFC, Corporate and Other. Majority of the company's revenue is generated from its Restaurant Group segment which represents the operations of O'Charley's and Ninety Nine Restaurants.